Eli Lilly raised its full-year 2026 sales forecast after reporting third-quarter earnings and revenue that beat analyst estimates. The company now expects revenue of $91 billion to $92 billion, up from its previous range of $85 billion to $87 billion. Its shares rose about 7% on Thursday.
Demand for Zepbound and Mounjaro drove the results. Mounjaro's worldwide revenue rose 65% to $10.72 billion for the quarter, with U.S. sales of about $5 billion. Analysts had expected $10.10 billion in worldwide sales. Zepbound posted $5.35 billion in revenue, up 49% from a year earlier, compared with analyst expectations of $5.09 billion.
The new obesity pill Foundayo fell short. It generated $184 million in third-quarter sales, below analyst forecasts of around $229 million, according to StreetAccount estimates. Lilly CFO Lucas Montarces said U.S. prescriptions for Foundayo and new patients on the drug doubled from the previous quarter. He said about 4 in 10 patients starting an oral obesity medicine choose Foundayo.
Lilly reported net income of $6.45 billion, or $7.22 per share, for the quarter. That figure includes $4.57 per share in charges tied to deals made during the quarter. Excluding one-time items, the company posted earnings of $7.48 per share. Lilly said its adjusted earnings guidance for 2026 is $35 to $36 per share, compared with a previous outlook of $35.50 to $36.50.
According to an earnings presentation, Lilly held 63% of the U.S. obesity and diabetes drug market in the third quarter, while Novo Nordisk held 36.6%. CEO Dave Ricks told CNBC that he estimates 3% to 10% of eligible patients in the U.S. currently access obesity care. He said the "room for expansion here of this market is dramatic."